Gencove, Element Biosciences join forces to offer cost-effective, low-pass WGS and analysis

By The Science Advisory Board staff writers

June 13, 2022 -- A joint marketing agreement between Gencove and Element Biosciences is meant to further reduce the cost and complexity of obtaining genomic information.

Gencove offers low-pass whole-genome sequencing and analysis software, while Element Biosciences is the developer of the Element Aviti System, a new and disruptive DNA sequencing platform. The companies contend that by combining the performance and flexibility of the Aviti System with Gencove's software platform will democratize access to genomic information.

"Gencove and Element share a vision to make cost-effective, high-throughput genome-wide information universally available," said Gencove CEO Joseph Pickrell, PhD, in a statement. "This agreement moves the industry closer to ubiquitous sequencing to help solve our civilization's most pressing biological challenges."

Element Biosciences partners with Agilent Technologies
Element Biosciences has partnered with Agilent Technologies to demonstrate the integration of Element’s AVITI System with Agilent Technologies’ industry-leading...

Copyright © 2022

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter